儿科患者 1 小时英夫利西单抗输注的回顾性队列分析

Q2 Medicine
Drew Goodrich, Alyssa George, Jennifer Stein, Robert Koziol, Brienne Costigan
{"title":"儿科患者 1 小时英夫利西单抗输注的回顾性队列分析","authors":"Drew Goodrich, Alyssa George, Jennifer Stein, Robert Koziol, Brienne Costigan","doi":"10.5863/1551-6776-30.1.65","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to characterize and assess the safety of a 1-hour infliximab infusion in a cohort of pediatric patients.</p><p><strong>Methods: </strong>A retrospective chart review of pediatric patients that received a 1-hour infliximab or its biosimilar infusion for a gastrointestinal or rheumatologic condition was conducted. Infusions were included if the patient had at least 3 infusions for rheumatology patients and 4 for gastroenterology patients. Patients who were not transitioned to the rapid, 1-hour infusion were excluded. Baseline characteristics, including age, weight, indication, dose, the use of premedications or combination therapy, and the development of anti-infliximab antibodies were analyzed along with any reported safety outcomes related to infusion administration.</p><p><strong>Results: </strong>A total of 69 pediatric patients were screened for inclusion, of which 41 patients received 159 infusions. The median age of the population was 15 years, and the sex distribution was nearly equal, with 48.8% of the population representing females. Most patients received infliximab treatment by the pediatric gastroenterology service (87.8%), with Crohn's disease being the lead indication (75.6%). A small number of patients were managed with combination therapy or premedicated before their infusion. Forty-one patients were routinely monitored for infliximab antibodies, but only 4 developed them (9.8%). Doses ranged from 150 to 1000 mg, depending on patient weight. One patient (0.6%) experienced an adverse reaction during the 1-hour infusion, which resulted in cessation of the infusion, but continued 1-hour infusions at a later date.</p><p><strong>Conclusions: </strong>This study showcases that 1-hour infliximab infusions are well-tolerated and appear safe in pediatric patients.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 1","pages":"65-69"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809531/pdf/","citationCount":"0","resultStr":"{\"title\":\"Retrospective Cohort Analysis of 1-Hour Infliximab Infusions in Pediatric Patients.\",\"authors\":\"Drew Goodrich, Alyssa George, Jennifer Stein, Robert Koziol, Brienne Costigan\",\"doi\":\"10.5863/1551-6776-30.1.65\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study aimed to characterize and assess the safety of a 1-hour infliximab infusion in a cohort of pediatric patients.</p><p><strong>Methods: </strong>A retrospective chart review of pediatric patients that received a 1-hour infliximab or its biosimilar infusion for a gastrointestinal or rheumatologic condition was conducted. Infusions were included if the patient had at least 3 infusions for rheumatology patients and 4 for gastroenterology patients. Patients who were not transitioned to the rapid, 1-hour infusion were excluded. Baseline characteristics, including age, weight, indication, dose, the use of premedications or combination therapy, and the development of anti-infliximab antibodies were analyzed along with any reported safety outcomes related to infusion administration.</p><p><strong>Results: </strong>A total of 69 pediatric patients were screened for inclusion, of which 41 patients received 159 infusions. The median age of the population was 15 years, and the sex distribution was nearly equal, with 48.8% of the population representing females. Most patients received infliximab treatment by the pediatric gastroenterology service (87.8%), with Crohn's disease being the lead indication (75.6%). A small number of patients were managed with combination therapy or premedicated before their infusion. Forty-one patients were routinely monitored for infliximab antibodies, but only 4 developed them (9.8%). Doses ranged from 150 to 1000 mg, depending on patient weight. One patient (0.6%) experienced an adverse reaction during the 1-hour infusion, which resulted in cessation of the infusion, but continued 1-hour infusions at a later date.</p><p><strong>Conclusions: </strong>This study showcases that 1-hour infliximab infusions are well-tolerated and appear safe in pediatric patients.</p>\",\"PeriodicalId\":37484,\"journal\":{\"name\":\"Journal of Pediatric Pharmacology and Therapeutics\",\"volume\":\"30 1\",\"pages\":\"65-69\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809531/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pediatric Pharmacology and Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5863/1551-6776-30.1.65\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5863/1551-6776-30.1.65","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在描述和评估一组儿科患者输注1小时英夫利昔单抗的安全性。方法:对胃肠道或风湿病患者接受1小时英夫利昔单抗或其生物类似药输注的儿科患者进行回顾性图表回顾。如果风湿病患者至少有3次输液,胃肠病患者至少有4次输液,则包括输液。未过渡到快速1小时输注的患者被排除在外。基线特征,包括年龄、体重、适应症、剂量、用药前或联合治疗的使用、抗英夫利昔单抗抗体的发展,以及与输注给药相关的任何报告的安全性结果进行了分析。结果:共筛选纳入69例儿科患者,其中41例患者接受159次输液。人口年龄中位数为15岁,性别分布基本相等,女性占48.8%。大多数患者接受了小儿胃肠科的英夫利昔单抗治疗(87.8%),其中克罗恩病是主要适应症(75.6%)。少数患者在输注前采用联合治疗或预先用药。41例患者常规监测英夫利昔单抗抗体,但仅有4例(9.8%)出现抗体。剂量从150毫克到1000毫克不等,取决于病人的体重。1例患者(0.6%)在1小时输注期间出现不良反应,导致停止输注,但随后继续输注1小时。结论:本研究显示1小时英夫利昔单抗在儿科患者中耐受性良好且安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Retrospective Cohort Analysis of 1-Hour Infliximab Infusions in Pediatric Patients.

Objective: This study aimed to characterize and assess the safety of a 1-hour infliximab infusion in a cohort of pediatric patients.

Methods: A retrospective chart review of pediatric patients that received a 1-hour infliximab or its biosimilar infusion for a gastrointestinal or rheumatologic condition was conducted. Infusions were included if the patient had at least 3 infusions for rheumatology patients and 4 for gastroenterology patients. Patients who were not transitioned to the rapid, 1-hour infusion were excluded. Baseline characteristics, including age, weight, indication, dose, the use of premedications or combination therapy, and the development of anti-infliximab antibodies were analyzed along with any reported safety outcomes related to infusion administration.

Results: A total of 69 pediatric patients were screened for inclusion, of which 41 patients received 159 infusions. The median age of the population was 15 years, and the sex distribution was nearly equal, with 48.8% of the population representing females. Most patients received infliximab treatment by the pediatric gastroenterology service (87.8%), with Crohn's disease being the lead indication (75.6%). A small number of patients were managed with combination therapy or premedicated before their infusion. Forty-one patients were routinely monitored for infliximab antibodies, but only 4 developed them (9.8%). Doses ranged from 150 to 1000 mg, depending on patient weight. One patient (0.6%) experienced an adverse reaction during the 1-hour infusion, which resulted in cessation of the infusion, but continued 1-hour infusions at a later date.

Conclusions: This study showcases that 1-hour infliximab infusions are well-tolerated and appear safe in pediatric patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pediatric Pharmacology and Therapeutics
Journal of Pediatric Pharmacology and Therapeutics Medicine-Pediatrics, Perinatology and Child Health
CiteScore
2.40
自引率
0.00%
发文量
90
期刊介绍: The Journal of Pediatric Pharmacology and Therapeutics is the official journal of the Pediatric Pharmacy Advocacy Group. JPPT is a peer-reviewed multi disciplinary journal that is devoted to promoting the safe and effective use of medications in infants and children. To this end, the journal publishes practical information for all practitioners who provide care to pediatric patients. Each issue includes review articles, original clinical investigations, case reports, editorials, and other information relevant to pediatric medication therapy. The Journal focuses all work on issues related to the practice of pediatric pharmacology and therapeutics. The scope of content includes pharmacotherapy, extemporaneous compounding, dosing, methods of medication administration, medication error prevention, and legislative issues. The Journal will contain original research, review articles, short subjects, case reports, clinical investigations, editorials, and news from such organizations as the Pediatric Pharmacy Advocacy Group, the FDA, the American Academy of Pediatrics, the American Society of Health-System Pharmacists, and so on.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信